Physician profile
Lori Edwards
NPI 1467983601
$7,973.95
in general payments reported to CMS, 2019-2025
32 companies · $2,748 in 2025
The $2,748 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $648 · 2022: $786 · 2023: $1,286 · 2024: $2,505 · 2025: $2,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,539.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,260.55 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $742.86 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $732.49 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $456.23 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $403.70 | 2023-2025 | Ibsrela |
| Celgene Corporation | $356.56 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $334.34 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $333.61 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $296.50 | 2021-2024 | Dificid |
| Gilead Sciences, INC. | $283.38 | 2022-2025 | Epclusa |
| Regeneron Healthcare Solutions, INC. | $251.25 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $162.94 | 2024-2025 | Vegzelma |
| Paratek Pharmaceuticals, INC. | $154.84 | 2021-2022 | |
| Melinta Therapeutics, LLC | $142.22 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $138.87 | 2023-2025 | Linzess |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $123.20 | 2024-2025 | Iqirvo |
| Cumberland Pharmaceuticals, INC. | $118.46 | 2021 | |
| Boston Scientific Corporation | $87.82 | 2024 | Axios |
| Intercept Pharmaceuticals, INC. | $78.74 | 2021-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $72.35 | 2022-2023 | |
| Exact Sciences Corporation | $66.59 | 2023 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $63.26 | 2021-2024 | Sutab, Suflave |
| Organon LLC | $58.15 | 2024-2025 | Hadlima |
| Ferring Pharmaceuticals INC. | $47.26 | 2022-2023 | Cimzia |
| Viiv Healthcare Company | $45.10 | 2021 | |
| Phathom Pharmaceuticals, INC. | $37.01 | 2024-2025 | Voquezna |
| Enterra Medical, INC. | $30.65 | 2024 | |
| Medtronic, INC. | $23.07 | 2023 | Interstim |
| Genzyme Corporation | $21.63 | 2025 | |
| Theratechnologies INC. | $18.51 | 2022 | |
| Vivus LLC | $17.21 | 2021 | |
| Novo Nordisk INC | $14.60 | 2025 | Saxenda, Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.